TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›NOV

NOV

NOV Inc.

Next earnings Jul 27, 2026 (after close) · consensus $0.16 EPS, $2.10B rev

Last earnings -2.5% on 2026-04-28

Hold
$18.02
▼ -2.22%
$18.02▲ +44.98%
over 1Y
L $11.60H $21.36
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-2.2%
1W-4.9%
1M-11.5%
3M-3.2%
YTD+11.3%
1Y+45.0%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Hold
Quality
C
Valuation
Overvalued
Filings
Watch
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 24 analysts
Buy

Oilfield-equipment maker in a cyclical earnings squeeze — net income -77% — but cheap on sales, debt-light and returning lots of cash.

Net income $145M · FY2025

The read

Middling fundamentals and a rich price (~84% above fair value) leave little margin of safety — a wait-and-see.

NOV is a global oilfield-equipment and technology supplier whose FY2025 results show a clear cyclical downturn in spending. Revenue slipped 1.4% to $8.74B, but profitability fell hard: gross profit dropped 12.1%, operating income fell 43.6% to $494M (a 5.6% margin), and net income collapsed 77.2% to $145M (EPS $0.39). Returns are depressed — 2.3% ROE — and the 47.8x P/E reflects trough earnings, not an expensive stock. On sales the valuation is undemanding at 0.8x.

The balance sheet and cash generation are the offsetting strengths. NOV is debt-light at 0.79x liabilities/equity ($1.69B long-term debt against $6.27B equity and $1.55B cash, up 26%), and it generated $1.25B of operating cash flow despite the earnings drop — confirming this is a cyclically-low-margin year, not a broken business. Capital return accelerated: $315M of buybacks (+38%) cut shares 5.4%, and the dividend rose 76% to $190M.

AI-generated analysis, produced by our proprietary engine from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:55 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$5.52B$7.24B$8.58B$8.87B$8.74B
Gross profit$774M$1.33B$1.83B$2.01B$1.77B
Operating income-$134M$264M$651M$876M$494M
Net income-$250M$155M$993M$635M$145M
Diluted EPS-$0.65$0.39$2.50$1.60$0.39
Net margin-4.5%2.1%11.6%7.2%1.7%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$6.63B
EV / EBITDA7.8
EV / Sales0.8
EV / FCF7.6
P / FCF7.4
PEG (trailing)—
Earnings yield2.2%
FCF yield13.5%

Quality & risk

ROIC (est.)4.9%
Free cash flow$876M
Total debt$1.72B
Net cash-$166M
Altman Z-Score1.98 grey
Piotroski F-Score5/9

Capital returns

Buyback yield4.9%
Dividend yield (est.)2.9%
Shareholder yield7.8%
Shares Δ YoY-5.4%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Shareholder vote2026-05-22
  2. 8-K Earnings results2026-04-28
  3. 10-Q Quarterly report2026-04-28
  4. 8-K Earnings results2026-04-15
  5. DEF 14A Proxy statement2026-04-09
  6. 8-K Officer / director change2026-03-18
  7. 8-K Officer / director change2026-02-20
  8. 10-K Annual report2026-02-12
  9. 8-K Earnings results2026-02-05

Recent filings

all on EDGAR ↗
11-KPeriod ending 2025-12-312026-06-22open ↗SDFiling2026-05-29open ↗8-KPeriod ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗4Period ending 2026-05-202026-05-22open ↗SCHEDULE 13G/AFiling2026-05-15open ↗

Quality score

C
ValueGrowthProfitHealthMom.
ValueC+
GrowthF
ProfitabilityC-
Financial healthA-
MomentumC+
  • ✗Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
  • ✗P/E below 25

Fair value est.

$2.83

Overvalued -84% vs price

cheapfair valueexpensive

Modified Graham: EPS $0.39 × (8.5 + 1.5 × 0.0% growth) × 0.85 quality = 7.3× multiple. An estimate, not a price target.

11.6052-week21.36
Revenue
$8.74B
-1.4% YoY
Net margin
1.7%
ROE
2.3%
P/E
46.2

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$8.74B-1.4%
Net income$145M-77.2%
Gross profit$1.77B-12.1%
Operating income$494M-43.6%
Diluted EPS$0.39-75.6%
Cash & equivalents$1.55B+26.2%
Total assets$11.3B-0.6%
Total liabilities$4.97B+0.7%
Stockholders' equity$6.27B-1.7%
Gross: 20.2%Op.: 5.6%L/E: 0.79x

Frequently asked

Is NOV Inc. (NOV) a buy?
NOV currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Oilfield-equipment maker in a cyclical earnings squeeze — net income -77% — but cheap on sales, debt-light and returning lots of cash.
What is NOV's fair value?
A Modified-Graham model based on NOV's SEC fundamentals estimates a fair value of about $2.83. It is an estimate from reported earnings, not a price target.
Is NOV overvalued or undervalued?
Against a Modified-Graham fair-value estimate, NOV currently appears overvalued relative to its SEC-grounded earnings power.
What is NOV Inc.'s quality score?
NOV scores 55.95710829860184/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001021860, latest 10-Q filed 2026-04-28) · EODHD · Proprietary analysis · as of 6/21/2026, 8:55:08 PM.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-05-20
Donadio Marcela E
Director
Award9.46K
2026-05-20
Chowbey Sanjay
Director
Award9.46K
2026-05-20
Martinez Patricia
Director
Award9.46K
2026-05-20
Welborn Robert S.
Director
Award9.46K
2026-05-20
Thomas William R.
Director
Award9.46K
2026-05-20
HARRISON DAVID D
Director
Award9.46K
2026-05-20
Kendall Christian S
Director
Award9.46K
2026-05-20
MELCHER PATRICIA B
Director
Award9.46K

Dividends

Quarterly
Yield (TTM)
2.3%
Annual / share
$0.42
Last ex-date
2026-06-12
Last amount
$0.09
ex 2026-06-12paid 2026-06-26$0.09
ex 2026-06-01paid 2026-06-12$0.09
ex 2026-03-13paid 2026-03-27$0.09
ex 2025-12-05paid 2025-12-19$0.08
ex 2025-09-12paid 2025-09-26$0.08
ex 2025-06-13paid 2025-06-27$0.08

Source: EODHD. Yield = trailing-12-month dividends ÷ price.

Earnings history

beat/miss · move
2026-04-28Miss -68.1% est▼ -2.55%8-K ↗
2026-04-15Miss -68.1% est▼ -0.42%8-K ↗
2026-02-05Miss -107.9% est▼ -5.88%8-K ↗
2025-10-28Miss -56.6% est▲ +7.17%8-K ↗
2025-07-29Miss -2.4% est▼ -7.98%8-K ↗
2025-04-29—▼ -1.96%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Congressional trades

all activity →

Disclosed under the STOCK Act

2025-08-13Lisa McClainSell$1.00K–$15.0KPTR ↗
2025-08-13Lisa McClainBuy$1.00K–$15.0KPTR ↗
2023-05-19Daniel GoldmanSell$1.00K–$15.0KPTR ↗
2023-04-17Daniel GoldmanBuy$1.00K–$15.0KPTR ↗
2015-11-30Bob GibbsSell$1.00K–$15.0KPTR ↗

Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.

Recent news

market news →
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?Bullish
finance.yahoo.com· 2026-07-02
3 Small-Cap Stocks We’re Skeptical OfBullish
finance.yahoo.com· 2026-06-30
Top Biotech Gainers: UPC Expands Patent Portfolio, All Eyes On SLS, What's Behind The QDEL Rumor?Bullish
nasdaq.com· 2026-06-30
NOV vs. SLB N.V.: Which Energy Stock Is a Better Buy in 2026?Bullish
nasdaq.com· 2026-06-28
NOV and Transocean Stocks Trade Down, What You Need To KnowBullish
finance.yahoo.com· 2026-06-24
AgomAb Aligns With FDA On Design Of Phase 2b NOV-ERA For Ontunisertib In Crohn's DiseaseBullish
nasdaq.com· 2026-06-24

Vs tracked universe

compare →

1194 tracked peers · median

TENK Score56 vs 67
Revenue growth-1.4% vs 7.5%
Net margin1.7% vs 10.0%
Return on equity2.3% vs 12.0%
P/E46.2 vs 26.2

News sentiment

EODHD · 19d
Bullish
+0.12
vs typical · 24 articles
↓ cooling

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.